Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTRA1 | Q92743 | 1/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5401096 | 0.90 | NR1H2 (0.42) | HTRA1UCHL1RORCCYP1A2POLB | |
| SCHEMBL7138214 | 0.86 | UCHL1 (0.44) | HTRA1UCHL1RORCCYP1A2POLB | |
| SCHEMBL9035380 | 0.84 | AGTR2 (0.43) | AGTR2ACEKMT2A | |
| SCHEMBL9034394 | 0.84 | AGTR2 (0.43) | AGTR2ACEKMT2A | |
| SCHEMBL9034390 | 0.84 | AGTR2 (0.43) | AGTR2ACEKMT2A | |
| SCHEMBL8390205 | 0.83 | GPR119 (0.39) | HTRA1UCHL1RORCHSD11B1KMT2A | |
| SCHEMBL8201900 | 0.83 | GPR119 (0.39) | HTRA1UCHL1RORCHSD11B1KMT2A | |
| SCHEMBL8211858 | 0.83 | GPR119 (0.39) | HTRA1UCHL1RORCHSD11B1KMT2A | |
| SCHEMBL8789793 | 0.83 | SRC (0.46) | RORCKMT2ANR1H2NR1H3ABCB1 | |
| SCHEMBL5404919 | 0.83 | SRC (0.46) | RORCKMT2ANR1H2NR1H3ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159622-A1 | COLLAGEN MIMICS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-05-25 | — | — | US | disclosed |
| US-11390662-B2 | Collagen mimics | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-07-19 | — | — | US | disclosed |
| US-10329341-B2 | Collagen mimics | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180030115-A1 | COLLAGEN MIMICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-01 | — | — | US | disclosed |
| US-9758569-B2 | Collagen mimics | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-09-12 | — | — | US | disclosed |
| US-20070275897-A1 | Collagen mimics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-29 | — | — | US | disclosed |
| EP-1303485-A1 | PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6541638-B2 | (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction | HOFFMAN-LA ROCHE INC. | 2003-04-01 | — | — | US | disclosed |
| US-20020049243-A1 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. | 2002-04-25 | — | — | US | disclosed |
| WO-2002006222-A1 | PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049243-A1 | Pyrrolidine derivatives | PREP, PEPD, DNPEP | HTRA1 477/4885UCHL1 343/4885AGTR2 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.